Investigational drug · Phase 3
Ilaprazole
Also called: the brand name, Noltec
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Peptic Ulcer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
35
Any phase or sponsor naming "Ilaprazole"
First trial start
2024
Jul 23, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ilaprazole", any sponsor or status.
Conditions studied
As listed on its trial records.
- Peptic Ulcer
Largest trials
Live from ClinicalTrials.gov: studies naming "Ilaprazole" as an intervention, largest first.
- Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive EsophagitisPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00471094 · 831 participants · Start May 2007 · Primary completion Oct 2007
Drug: Ilaprazole; Ilaprazole and 2 more · For: Esophagitis
Sites: Hueytown, Alabama; Huntsville, Alabama; Chandler, Arizona · 94 sites in all
- Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal BleedingPivotal-lookingNot yet recruiting
West China HospitalAcademic, hospital or other
NCT05624229 · 672 participants (planned) · Start Oct 1, 2023 · Primary completion Dec 31, 2025
Drug: Proton Pump Inhibitors; No Proton Pump Inhibitors · For: Upper Gastrointestinal Hemorrhage
- Influence of Oral Hp Infection and Oral Related Factors on Gastric Hp Infection and Eradication TherapyStatus unknown
Second Affiliated Hospital of Xi'an Jiaotong UniversityAcademic, hospital or other
NCT05455372 · 600 participants (planned) · Start Jul 8, 2022 · Primary completion Sep 30, 2023
Drug: PPI quadruple therapy · For: Helicobacter Pylori Infection
Sites: Xi'an, China
- Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese PatientsPivotal-lookingCompleted
Livzon Pharmaceutical Group Inc.Industry
NCT02860624 · 550 participants · Start Dec 2011 · Primary completion Apr 2013
Drug: 10 mg ilaprazole; 40mg esomeprazole · For: Gastroesophageal Reflux Disease
- Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese PatientsPivotal-lookingCompleted
Livzon Pharmaceutical Group Inc.Industry
NCT03362281 · 540 participants · Start Oct 2014 · Primary completion Apr 2015
Drug: Ilaprazole; Omeprazole and 2 more · For: Peptic Ulcer Hemorrhage
- Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 3)Pivotal-lookingCompleted
Livzon Pharmaceutical Group Inc.Industry
NCT00952978 · 496 participants · Start Sep 2005 · Primary completion Feb 2006
Drug: 10 mg ilaprazole; 20 mg omeprazole · For: Duodenal Ulcer
Sites: Beijing, China
- Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori TreatmentPivotal-lookingStatus unknown
Shandong UniversityAcademic, hospital or other
NCT02988089 · 480 participants (planned) · Start Apr 20, 2017 · Primary completion Sep 2017
Drug: Clarithromycin susceptibility dependant strategy; 2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline ) and 4 more · For: Helicobacter Pylori Infection; Antimicrobial Susceptibility Testing
Sites: Ji'nan, China
- A Multi-center, Double-blinding, Parallel and Positive-controlled Phase III Clinical Trial for Efficacy and Safety Evaluation of Ilaprazole Sodium for Injection on Prevention of Stress Ulcer BleedingPivotal-lookingCompleted
Livzon Pharmaceutical Group Inc.Industry
NCT05841394 · 449 participants · Start Jul 16, 2021 · Primary completion Apr 28, 2022
Drug: Esomeprazole 40mg; Ilaprazole Sodium and 2 more · For: Stress Ulcer Bleeding
Sites: Shanghai, China; Ürümqi, China
- Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic UlcerPivotal-lookingActive, not recruiting
Il-Yang Pharm. Co., Ltd.Industry
NCT06284876 · 416 participants (planned) · Start Jul 23, 2024 · Primary completion Aug 30, 2027
Drug: Ilaprazole; Lansoprazole and 2 more · For: Peptic Ulcer
Sites: Seoul, South Korea · 2 sites in all
- Ilaprazole for the Treatment of Duodenal Ulcer in Chinese PatientsPivotal-lookingCompleted
Livzon Pharmaceutical Group Inc.Industry
NCT02847455 · 408 participants · Start Aug 2008 · Primary completion Oct 2009
Drug: 5 mg ilaprazole; 10 mg ilaprazole and 1 more · For: Duodenal Ulcer
Newest research
PubMed records naming it or its code names, newest first.
- Rabeprazole exhibits broad-spectrum fusion inhibition against Nipah pseudovirus and authentic HCoV-OC43 and RSV.
Shen Y, Wang B, Li J, et al. · Bioorg Chem 2026
- Cytochrome P450 Enzymes in the Metabolism of Proton Pump Inhibitors: Implications for the Treatment of Peptic Ulcers.
Sharma CB, Yadav S, Prajapati S · Curr Drug Targets 2026
- Comparative effectiveness of genotype-guided and empirical bismuth-containing quadruple therapy for Helicobacter pylori eradication: a retrospective study.
Wang P, Yang M, Zhao X, et al. · Front Pharmacol 2026
- Assessment of Pharmacokinetic Interaction and Clinical Efficacy of Clopidogrel Co-administered with Ilaprazole.
N D, A P, T M V, et al. · Clin Pharmacol Drug Dev 2026
- An Evaluation of the Inhibitory Effect of Apatinib on Ilaprazole Metabolism: in vitro, in vivo and in silico Study.
Li R, Jiang S, Chen Y, et al. · Drug Des Devel Ther 2026
- Ilaprazole Versus Esomeprazole for Artificial Ulcer Healing After Gastric Endoscopic Submucosal Dissection: A Single-Center Retrospective Study.
Ryu DG, Kim SJ, Park SB, et al. · J Clin Med 2026
Also in development for Peptic Ulcer
- JP-1366Phase 34 trials
Onconic Therapeutics Inc. · H. Pylori Eradication Therapy, Non-erosive Gastroesophageal Reflux Disease, Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.